Back

Natural history and predictors of all-cause mortality and major arrhythmic cardiac events in pediatric RASopathy associated hypertrophic cardiomyopathy

27 August 2023 (14:15 - 14:55)
Organised by: Logo
Congress Presentation Part of: Hypertrophic cardiomyopathy risk prediction and stratification: death, heart failure, and arrhythmia Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Olga Boleti

University College London, London (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
The challenge of risk stratification in hypertrophic cardiomyopathy: clinical, genetic and imaging insights from a quaternary referral centre
Doctor E. Paratz (Melbourne, AU)
Abstract Slides Video
Presentation thumbnail
Mortality in hypertrophic cardiomyopathy is unrelated to genotype
Doctor J. Bonaventura (Prague, CZ)
Abstract Slides Video
Presentation thumbnail
Prediction of cardiac death in patients with hypertrophic cardiomyopathy using RNA-sequencing of plasma small non-coding RNAS
Doctor K. Akita (New York, US)
Abstract Slides Video
Presentation thumbnail
Prediction of acute heart failure events in patients with hypertrophic cardiomyopathy using RNA-Sequencing of plasma small non-coding RNAs
Doctor K. Akita (New York, US)
Abstract Slides Video
Presentation thumbnail
Perfomance of sudden cardiac death prediction strategies before and after Septal Reduction Strategies in patients with Hypertrophic Cardiomyopathy
Doctor N. Maurizi (Lausanne, CH)
Abstract Slides Video

Access the full session

Session thumbnail
Hypertrophic cardiomyopathy risk prediction and stratification: death, heart failure, and arrhythmia

The Event

Event poster

ESC Congress 2023

27 August 2023 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Phenotype progression in pediatric RASopathy-associated hypertrophic cardiomyopathy
thumbnail
Congress Presentation
Sudden cardiac death in childhood RASopathy-associated hypertrophic cardiomyopathy: validation of HCM Risk-Kids model and predictors of events
thumbnail
Congress Presentation
Long-term clinical benefit of mavacamten for hypertrophic cardiomyopathy in a patient with RAF1-associated noonan syndrome

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources